Sanofi Deal History & Licensing Activity
Sanofi is a large pharma headquartered in France. Over the past three years, Sanofi has been involved in 17 licensing and acquisition transactions, with a primary focus on Small Molecules (7 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
6
Active Trials
50
Top Modality
Small Molecules
Focus Area
Autoimmune
Sanofi Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sanofi in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| KT-485 (SAR447971) | Kymera Therapeutics | Small Molecules | Phase 1 | collaboration | Jun 9, 2026 |
| 13 anti-tuberculosis and anti-infective brands portfolio | Gujarat Themis Biosyn | Small Molecules | Approved | acquisition | Apr 23, 2026 |
| rovadicitinib | Sino Biopharm (Chia Tai Tianqing) | Small Molecules | Unknown | license | Mar 4, 2026 |
| Undisclosed | Earendil Labs | Bispecific Antibodies | Discovery | collaboration | Jan 5, 2026 |
| HEPLISAV-B; Z-1018 shingles vaccine | Dynavax Technologies | Vaccines | Approved | acquisition | Dec 24, 2025 |
| ADEL-Y01 | ADEL | Other | Unknown | license | Dec 16, 2025 |
Sanofi Pipeline Focus
Therapeutic areas and modalities where Sanofi is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Sanofi Strategic Signals
Key indicators of Sanofi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Sanofi Clinical Pipeline
Sanofi has 50 active clinical trials across 8 development phases.
3
Phase 4
8
Unknown
2
Not Applicable
8
Phase 1
3
Phase 1/2
10
Phase 2
1
Phase 2/3
15
Phase 3
See How Your Asset Matches Sanofi's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Vaccines Benchmarks
Upfront, milestone, and royalty benchmarks for vaccines deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Sanofi Licensing & Deal Activity
Sanofi is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 17 deals over the past three years, Sanofi ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi include Autoimmune (13 deals and trials), Immunology (8 deals and trials), Infectious (8 deals and trials), and Infectious Disease (5 deals and trials). In terms of modality, Sanofi has shown particular interest in small molecules, vaccines, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Sanofi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.